Search research articles
Contact Us
Filters
Showing results (201-210 of 377) with videos related to
Page
of 38
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
September 20, 2017
Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE)
Sibylle Loibl, Lorena de la Pena, Valentina Nekljudova, et al.
NPJ Breast Cancer
|
September 18, 2022
Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
Sibylle Loibl, Chiun-Sheng Huang, Max S Mano, et al.
Geburtshilfe Und Frauenheilkunde
|
June 13, 2025
Indirect Treatment Comparison between Ribociclib Combined with Non-Steroidal Aromatase Inhibitors and Ovarian Function Suppression vs. Tamoxifen in Premenopausal Women with Early Breast Cancer
Diana Lüftner, Maggie Banys-Paluchowski, Andreas D Hartkopf, et al.
The Oncologist
|
January 30, 2013
Analysis of regional timelines to set up a global phase III clinical trial in breast cancer: the adjuvant lapatinib and/or trastuzumab treatment optimization experience
Otto Metzger-Filho, Evandro de Azambuja, Ian Bradbury, et al.
Breast Cancer Research and Treatment
|
November 1, 2016
A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study
Nadia Harbeck, Steffen Saupe, Elke Jäger, et al.
Breast Cancer Research : BCR
|
January 25, 2025
Prediction of pathological complete response after neoadjuvant chemotherapy for HER2-negative breast cancer patients with routine immunohistochemical markers
Lothar Häberle, Ramona Erber, Paul Gass, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 15, 2009
Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer
Michael Untch, Volker Möbus, Walther Kuhn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 19, 2023
RANK Expression as an Independent Predictor for Response to Neoadjuvant Chemotherapy in Luminal-Like Breast Cancer: A Translational Insight from the GeparX Trial
Theresa Link, Jens-Uwe Blohmer, Wolfgang D Schmitt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 19, 2016
Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer
Barbara Ingold Heppner, Michael Untch, Carsten Denkert, et al.
The Lancet. Oncology
|
March 5, 2018
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
Sibylle Loibl, Joyce O'Shaughnessy, Michael Untch, et al.
Page
of 38
Search research articles
Search
Showing results (201-210 of 377) with videos related to
Sort By:
Page
of 38
European Journal of Cancer (Oxford, England : 1990)
|
September 20, 2017
Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE)
Sibylle Loibl, Lorena de la Pena, Valentina Nekljudova, et al.
NPJ Breast Cancer
|
September 18, 2022
Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
Sibylle Loibl, Chiun-Sheng Huang, Max S Mano, et al.
Geburtshilfe Und Frauenheilkunde
|
June 13, 2025
Indirect Treatment Comparison between Ribociclib Combined with Non-Steroidal Aromatase Inhibitors and Ovarian Function Suppression vs. Tamoxifen in Premenopausal Women with Early Breast Cancer
Diana Lüftner, Maggie Banys-Paluchowski, Andreas D Hartkopf, et al.
The Oncologist
|
January 30, 2013
Analysis of regional timelines to set up a global phase III clinical trial in breast cancer: the adjuvant lapatinib and/or trastuzumab treatment optimization experience
Otto Metzger-Filho, Evandro de Azambuja, Ian Bradbury, et al.
Breast Cancer Research and Treatment
|
November 1, 2016
A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study
Nadia Harbeck, Steffen Saupe, Elke Jäger, et al.
Breast Cancer Research : BCR
|
January 25, 2025
Prediction of pathological complete response after neoadjuvant chemotherapy for HER2-negative breast cancer patients with routine immunohistochemical markers
Lothar Häberle, Ramona Erber, Paul Gass, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 15, 2009
Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer
Michael Untch, Volker Möbus, Walther Kuhn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 19, 2023
RANK Expression as an Independent Predictor for Response to Neoadjuvant Chemotherapy in Luminal-Like Breast Cancer: A Translational Insight from the GeparX Trial
Theresa Link, Jens-Uwe Blohmer, Wolfgang D Schmitt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 19, 2016
Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer
Barbara Ingold Heppner, Michael Untch, Carsten Denkert, et al.
The Lancet. Oncology
|
March 5, 2018
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
Sibylle Loibl, Joyce O'Shaughnessy, Michael Untch, et al.
Page
of 38